Adipocytokine Profiling and Cardiovascular Risk Stratification in Rheumatoid Arthritis: Literature Review
- 1Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
- 2Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, 020475 Bucharest, Romania
- 32nd Department of Internal Medicine, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania
Abstract
Rheumatoid arthritis (RA) is associated with an increased burden of cardiovascular disease (CVD), reflecting interactions among persistent systemic inflammation, traditional cardiometabolic risk factors, and treatment exposure. Conventional risk scores may underestimate cardiovascular risk in some patients with RA. This narrative review examines the potential role of adipokines in linking synovial inflammation and metabolic dysfunction to vascular disease. It discusses the context-dependent cardiovascular associations of adiponectin, the pro-inflammatory signaling of leptin, resistin, visfatin, and chemerin, and the proposed protective roles of omentin, vaspin, and apelin. Emerging observations connect adipokine profiles with measures of subclinical atherosclerosis and selected clinical outcomes; however, methodological heterogeneity and residual confounding constrain causal and prognostic interpretations. We also consider venous thromboembolism, cardiometabolic multimorbidity, and treatment-related risk, including the clinical safety context of JAK inhibitors. At present, adipokine profiling remains investigational and should complement research, not replace established cardiovascular risk assessment and control of disease activity and conventional risk factors.
Related
- A Literature Review on the Waist Circumference Criteria for Metabolic Syndrome in Japan: Evidence and Implications for Cardiovascular Risk Stratification
- A Literature Review on the Waist Circumference Criteria for Metabolic Syndrome in Japan: Evidence and Implications for Cardiovascular Risk Stratification
- Multifactorial lifestyle interventions in rheumatoid arthritis: a systematic literature review
- Haemophagocytic Lymphohistiocytosis Triggered by Visceral Leishmaniasis Masquerading as Epstein-Barr Virus (EBV)-Associated Haemophagocytic Lymphohistiocytosis in Rheumatoid Arthritis: A Case Report and Literature Review
- Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis : A real-world disproportionality and machine learning analysis
BibTeX
@article{elsayed2026adipocytokine,
title = {{Adipocytokine Profiling and Cardiovascular Risk Stratification in Rheumatoid Arthritis: Literature Review}},
author = {Abdalla Elsayed and Abdulrahman Ismaiel and Mihai Bojinca},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218445},
url = {https://www.mdpi.com/2077-0383/15/21/8445},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adipocytokine Profiling and Cardiovascular Risk Stratification in Rheumatoid Arthritis: Literature Review
AU - Abdalla Elsayed
AU - Abdulrahman Ismaiel
AU - Mihai Bojinca
PY - 2026
DA - 2026/10/29
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218445
UR - https://www.mdpi.com/2077-0383/15/21/8445
AB - Rheumatoid arthritis (RA) is associated with an increased burden of cardiovascular disease (CVD), reflecting interactions among persistent systemic inflammation, traditional cardiometabolic risk factors, and treatment exposure. Conventional risk scores may underestimate cardiovascular risk in some patients with RA. This narrative review examines the potential role of adipokines in linking synovial inflammation and metabolic dysfunction to vascular disease. It discusses the context-dependent cardiovascular associations of adiponectin, the pro-inflammatory signaling of leptin, resistin, visfatin, and chemerin, and the proposed protective roles of omentin, vaspin, and apelin. Emerging observations connect adipokine profiles with measures of subclinical atherosclerosis and selected clinical outcomes; however, methodological heterogeneity and residual confounding constrain causal and prognostic interpretations. We also consider venous thromboembolism, cardiometabolic multimorbidity, and treatment-related risk, including the clinical safety context of JAK inhibitors. At present, adipokine profiling remains investigational and should complement research, not replace established cardiovascular risk assessment and control of disease activity and conventional risk factors.
SN - 2077-0383
ER -